Results 1 to 10 of about 1,941 (170)
Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases
Bruton’s tyrosine kinase (BTK) plays a crucial role in B-cell receptor and Fc receptor signaling pathways. BTK is also involved in the regulation of Toll-like receptors and chemokine receptors.
Datong Zhang, Fancui Meng
exaly +3 more sources
Objective: B-cell antigen receptor (BCR) signaling is required to maintain the physiological functions of normal B cells and plays an important pathogenic role in B-cell malignancies. Bruton tyrosine kinase (BTK), a critical mediator of BCR signaling, is
Liao Wang +7 more
doaj +1 more source
Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK [PDF]
Since Dr. Ogden Bruton’s 1952 paper describing the first human primary immunodeficiency disease, the peripheral membrane binding signaling protein, aptly named Bruton’s tyrosine kinase (BTK), has been the target of intense study. Dr. Bruton’s description of agammaglobulinemia set the stage for ultimately understanding key signaling steps emanating from
Lauren E. Kueffer +2 more
openaire +3 more sources
Novel antiplatelet strategies targeting GPVI, CLEC-2 and tyrosine kinases
Antiplatelet medications comprise the cornerstone of treatment for diseases that involve arterial thrombosis, including acute coronary syndromes (ACS), stroke and peripheral arterial disease.
Maan H. Harbi +4 more
doaj +1 more source
Megjegyzések a lokális Craig interpolációhoz
Zalán Molnár, Övge Öztürk
doaj +1 more source
Structure-based virtual screening and biological evaluation of novel small-molecule BTK inhibitors
Bruton tyrosine kinase (BTK) is linked to multiple signalling pathways that regulate cellular survival, activation, and proliferation. A covalent BTK inhibitor has shown favourable outcomes for treating B cell malignant leukaemia.
Tony Eight Lin +10 more
doaj +1 more source
Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib.
Bruton's tyrosine kinase (BTK) is the target of the therapeutic agent, Ibrutinib, that treats chronic lymphocyte leukemia (CLL), mantle cell lymphoma (MCL) and other B cell malignancies. Ibrutinib is a first in class, covalent BTK inhibitor that limits B-
David Y Lin, Amy H Andreotti
doaj +2 more sources
Az elmúlt évtizedekben egyre nagyobb figyelmet kap a környezeti problémák és az ezzel ös - szefüggő társadalmi jelenségek vizsgálata. Az egyetemi hallgatók környezettudatosságának és környezettudatosságukat befolyásoló tényezőknek a megismerése ...
Ferenc Mónus +2 more
doaj +1 more source
Chronic lymphocytic leukemia is a common form of leukemia and is dependent on growth-promoting signaling via the B-cell receptor. The Bruton tyrosine kinase (BTK) is an important mediator of B-cell receptor signaling and the irreversible BTK inhibitor ...
Rachael Arthur +3 more
doaj +1 more source
Stimulation of the catalytic activity of the tyrosine kinase Btk by the adaptor protein Grb2
The Tec-family kinase Btk contains a lipid-binding Pleckstrin homology and Tec homology (PH-TH) module connected by a proline-rich linker to a ‘Src module’, an SH3-SH2-kinase unit also found in Src-family kinases and Abl. We showed previously that Btk is
Laura M Nocka +4 more
doaj +1 more source

